Markets - BioReview (Page 3)

Pharmaceuticals

Beyond Zepbound: What Lilly's Retatrutide Data Tells Us About the Next Frontier of Metabolic Medicine

Eli Lilly's Phase 3 retatrutide data reveals a triple-acting metabolic drug that may push weight loss efficacy beyond tirzepatide, with patients losing up to 15% of body weight over 40 weeks—and the trajectory still heading downward.

Biotechnology

The Pill Race: How Structure Therapeutics Just Changed the Oral GLP-1 Calculus

Structure Therapeutics' aleniglipron showed 15% weight loss in Phase 2 trials, delivering injectable-like efficacy in pill form and reshaping the competitive landscape for oral GLP-1 obesity drugs.

Pharmaceuticals

The $400 Billion Orphan: How Rare Disease Drugs Became Pharma's Most Resilient Franchise

Evaluate's 2026 Orphan Drug Report projects rare disease drug sales will exceed $400 billion by 2032. Behind the headline number lies a more complicated story about FDA volatility, IRA policy shifts, and the structural forces reshaping who wins in rare disease medicine.

Policy

When Geopolitics Hits the Hospital: The Stryker Cyberattack and the New Vulnerability of Medtech

Shortly after midnight on March 11, 2026, thousands of Stryker employees discovered their devices had been wiped by Handala, a pro-Iran hacktivist group. The attack exposes a critical vulnerability: medtech companies can no longer assume neutrality in geopolitical conflicts.

Biotechnology

After the Vaccine: What BioNTech's Founder Exodus Reveals About the Future of mRNA

BioNTech's co-founders are stepping down to launch a new mRNA startup. What does this mean for the company's oncology pipeline and the future of mRNA technology?

Markets

Lilly's Employer Gambit: How the GLP-1 Giant Is Rewriting the Rules of Drug Distribution

Eli Lilly's new Employer Connect platform lets workers buy Zepbound at $449/month, bypassing insurers entirely. It is a bold bet that pharma companies can rewrite the rules of drug distribution before compounders and insurers do it for them.

Pharmaceuticals

Canada's Generic Ozempic Revolution Begins Today: Vimy Pharma Leads Charge as Patent Protections Expire

January 4, 2026, marks a watershed moment in the global GLP-1 market as Canada becomes the first country where Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic loses patent protection. Leading the charge into this newly opened market is Toronto-based Vimy Pharma, a startup founded

Biotechnology

BioMarin's $4.8 Billion Amicus Acquisition Reshapes Rare Disease Landscape

BioMarin Pharmaceutical's announcement of its $4.8 billion acquisition of Amicus Therapeutics represents one of the most significant consolidation moves in the rare disease sector, signaling a new era of strategic positioning as companies seek to build comprehensive portfolios in specialized therapeutic areas. The all-cash transaction, announced

Biotechnology

AbbVie's $1.2 Billion Zelgen Deal Signals Major Push Into T-Cell Engager Market

AbbVie kicked off 2026 with a strategic bang, announcing a potentially $1.2 billion licensing deal with China's Suzhou Zelgen Biopharmaceuticals for exclusive rights to develop and commercialize alveltamig (ZG-006) outside of Greater China. The New Year's Eve agreement represents one of the largest T-